Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

R), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint. Importantly, the trial also confirmed the positive results seen in the first Phase III trial with microplasmin. The results of the second Phase III trial (TG-MV-007) were presented for the first time at the American Society of Retina Specialists (ASRS) Annual Meeting by Dr. J. Michael Jumper (West Coast Retina and Medical Group and California Pacific Medical Center, California, USA). The trial recruited 326 patients at 48 centers in Europe and the U.S.

The detailed positive results from the first Phase III trial in the microplasmin MIVI-TRUST program (TG-MV-006) were presented at the World Ophthalmology Congress in Berlin in June 2010. The pooled results of both trials will be presented at the upcoming EURETINA (European Society of Retina Specialists) Congress in Paris, France, on September 4 by Prof. Peter Stalmans (University Hospitals Leuven, Belgium).

In his presentation at ASRS, Dr. Jumper highlighted that the TG-MV-007 study had met its primary endpoint, with 25.3% of the 245 microplasmin treated patients achieving resolution of their VMA at 28 days, compared to 6.2% of the 81 patients who received a placebo injection, a highly statistically significant result (p=0.001). In patients without epiretinal membrane, microplasmin was shown to be even more effective with 34.5% of patients seeing resolution of their VMA at 28 days, compared to 6.4% of placebo treated patients. Epiretinal membrane is a layer of scar tissue which builds up on the macula, making it more difficult to achieve resolution of VMA without surgical intervention. Epiretinal membrane can be easily identified using Optical Coherence Tomography (OCT).


'/>"/>
SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... PRINCETON, N.J. , July 24, 2014 /PRNewswire/ ... largest provider of regulatory and ethical review services ... acquired Alliance Biosciences. Formerly a division of ... Biosciences was the leading biosafety and biosecurity consulting ... . With this addition, WCG,s biosafety division – ...
(Date:7/24/2014)... 24, 2014 Draper University, a ... proud to announce that for 6 weeks this ... will converge on the Draper University campus in ... experiential program focused on entrepreneurship, building real-world skills, ... currently running its sixth cohort, continues to refresh ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
Breaking Biology Technology:3 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Recurring Disposables, Services and Accessories Revenue Up ... Catheter Launch Provided, ST. LOUIS, March 3 ... fourth quarter and full year,ended December 31, 2007., ... $39.3 million,compared with $27.2 million in 2006. Sales of ...
... Rochelle, NY, February 29, 2008 miRNA research ... in the life science world, reports Genetic Engineering ... are studying the effects of over- or underexpression ... of pathogenesis in a variety of diseases, according ...
... 29 DW Healthcare Partners (DWHP),a healthcare ... sale of one,of its portfolio companies, NWT ... Holdings (LabCorp(R)), one of the world,s largest,clinical ... UT, Tandem,Labs is a leading bioanalytical and ...
Cached Biology Technology:Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
(Date:7/25/2014)... detected an unknown interaction between microorganisms and salt. When ... droplet of salt water and is left to dry, ... biosaline 3D morphologically complex formations, where they hibernate. Afterwards, ... discovery was made by chance with a home microscope, ... journal and may help to find signs of ...
(Date:7/24/2014)... loss leads to conflict among people around the world, ... (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) Program ... to tackle global biodiversity decline. , The harvest of ... people and provides protein for more than a billion ... surprise that today,s unprecedented loss of wildlife, is bringing ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Bacteria manipulate salt to build shelters to hibernate 2New study draws links between wildlife loss and social conflicts 2
... PARTEQ Innovations, the technology commercialization office of Queen,s ... federal government towards the establishment of a National ... of Green Chemistry technologies. The first ... Canada will bring together Canada,s leading Green Chemistry ...
... of London have discovered how changes to a frog,s immune ... which is devastating frog populations across the UK. ... by a foreign virus which is estimated to be killing ... When it strikes garden ponds, the surrounding lawn becomes strewn ...
... p53 protects against cancer and is usually described as ... at the Swedish medical university Karolinska Institutet have now ... activity of p53. As the regulation mechanism is relatively ... the mystery of cancer. The p53 gene makes ...
Cached Biology News:Queen's receives $9.1 million to establish National Center of Excellence in green chemistry 2Queen's receives $9.1 million to establish National Center of Excellence in green chemistry 3Frog's immune system is key in fight against killer virus 2Newly discovered gene plays vital role in cancer 2
Request Info...
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
Biology Products: